Cellebrite DI (NASDAQ:CLBT) CEO Thomas Hogan Sells 139,713 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CEO Thomas Hogan sold 139,713 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the completion of the sale, the chief executive officer directly owned 790,548 shares in the company, valued at $12,166,533.72. This trade represents a 15.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cellebrite DI Price Performance

NASDAQ:CLBT traded down $4.45 during mid-day trading on Thursday, hitting $10.80. The company’s stock had a trading volume of 36,666,491 shares, compared to its average volume of 2,106,110. The business’s fifty day moving average is $14.59 and its two-hundred day moving average is $14.09. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of 38.57, a PEG ratio of 1.99 and a beta of 1.18. Cellebrite DI Ltd. has a 1 year low of $9.58 and a 1 year high of $19.98.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its holdings in shares of Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares during the period. Advisory Services Network LLC purchased a new stake in Cellebrite DI in the 3rd quarter valued at about $40,000. CWM LLC lifted its position in Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after buying an additional 889 shares during the last quarter. Elevation Wealth Partners LLC acquired a new position in Cellebrite DI in the second quarter valued at about $44,000. Finally, First Horizon Corp boosted its stake in Cellebrite DI by 421.8% during the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after buying an additional 2,337 shares during the period. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

CLBT has been the topic of several recent research reports. DA Davidson upped their price objective on Cellebrite DI from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Finally, Needham & Company LLC decreased their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Cellebrite DI presently has a consensus rating of “Moderate Buy” and an average price target of $21.80.

More Cellebrite DI News

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite reported second-quarter adjusted earnings of $0.11 per share, above the $0.06 consensus estimate, and highlighted rising subscription revenue in its first-half results. The company also raised its adjusted EBITDA target. Cellebrite Appoints Shiven Ramji Chief Executive Officer and Reports Second-Quarter 2026 Results
• Positive Sentiment: Unusually heavy call-option activity—19,988 contracts purchased versus an average of 586—suggested that some traders were positioning for a rebound or higher future prices, although options activity does not guarantee a change in fundamentals.
• Neutral Sentiment: Cellebrite appointed Shiven Ramji as chief executive officer, succeeding Thomas E. Hogan. The transition could bring a new growth strategy, but it also adds uncertainty while the company is lowering its outlook. Cellebrite CEO Appointment and Second-Quarter Results
• Neutral Sentiment: Two executives reported small stock sales totaling 641 shares. The transactions reduced their individual holdings by less than 0.2% and appear unlikely to materially affect the investment case.
• Negative Sentiment: Second-quarter revenue was $131.14 million, slightly below the $131.87 million analyst estimate. One earnings analysis also characterized adjusted earnings of $0.11 per share as below its $0.12 estimate, reinforcing concerns about execution. Cellebrite Q2 Earnings and Revenues Miss Estimates
• Negative Sentiment: Management lowered full-year 2026 revenue guidance to $555 million-$561 million from a consensus estimate of $568.1 million and forecast third-quarter revenue of $145 million-$148 million versus $150.3 million expected. The company also lowered its full-year ARR outlook.
• Negative Sentiment: Ademi LLP and Block & Leviton separately announced investigations into potential securities-law violations and allegedly inaccurate company statements. These announcements increase legal and reputational risk, although they represent claims under investigation rather than established wrongdoing. Ademi LLP Cellebrite Investigation

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.